A new study reveals the connection between the liver and brain in the context of metabolic liver disease
en-GBde-DEes-ESfr-FR

A new study reveals the connection between the liver and brain in the context of metabolic liver disease


A multidisciplinary research team has discovered that liver alterations associated with metabolic dysfunction–associated fatty liver disease (MASLD) can directly cause cognitive and neurological impairments, and that these effects can be reversed by a therapy exclusively targeting the liver. The findings, published in Science Advances, establish the existence of a “liver–brain axis” that is not only clinically relevant but also therapeutically actionable. The study, led by Dr. Malu Martínez-Chantar, Principal Investigator at the Liver Disease Laboratory at CIC bioGUNE, member of BRTA, and co-led by Teresa Cardoso Delgado, Ikerbasque Research Associate Professor at IIS Biobizkaia, demonstrates that animal models of diet-induced metabolic liver disease show alterations in social memory and sensory processing, accompanied by dysfunctions in the hippocampus, a key region for memory and learning.

Most promisingly, these alterations were reversed by treating the liver with an innovative siRNA-based therapy targeting CNNM4, a magnesium transporter altered in this hepatic condition, using a highly specific GalNAc-siRNA delivery system.

“Our work demonstrates that fatty liver and hepatic inflammation can directly affect the brain and behavior. This opens up an entirely new therapeutic avenue: treating the liver to improve cognitive function,” explains Malu Martínez-Chantar.

“Moreover, we show how cutting-edge molecular biology technologies and targeted therapies can have a real impact on brain function, combining precision and efficacy,” adds Teresa Cardoso Delgado.

This groundbreaking study was made possible thanks to unprecedented institutional collaboration, bringing together leading research groups such as those of Benedicto Crespo-Facorro (Translational Psychiatry, IBiS), Manuel Romero Gómez (SeLiver, IBiS), Ander Matheu (Cellular Oncology, IIS Biogipuzkoa), Javier Crespo (Digestive Diseases, IDIVAL), the Proteomics Platform at CIC bioGUNE, and Rubén Nogueiras (Physiology, CIMUS). It also involved five CIBER programs: CIBERer, CIBERSAM, CIBERobn, CIBERfes, and CIBERehd.

Teresa Cardoso Delgado et al. ,Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy.Sci. Adv.11,eady9758(2025).DOI:10.1126/sciadv.ady9758
Regions: Europe, Spain
Keywords: Health, Medical, Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Referenzen

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Wir arbeiten eng zusammen mit...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement